
Product Data Sheet

Product Name: SK1-I
 Cat. No.: GC61597

Chemical Properties

Cas. No. 1072443-89-0

SMILES OC[C@H]([C@H](/C=C/C1=CC=C(C=C1)CCCC)O)NC

Formula $C_{17}H_{27}NO_2$ M.Wt 277.4

Solubility Storage Store at $-20^{\circ}C$

General tips For obtaining a higher solubility, please warm the tube at $37^{\circ}C$ and shake it in the ultrasonic bath for a while. Stock solution can be stored below $-20^{\circ}C$ for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure

Background

SK1-I (BML-258), an analog of sphingosine, is an isozyme-specific competitive SPHK1 inhibitor with a K_i value of $10\ \mu M$ [1]. SK1-I shows no activity at SPHK1, PKC α , PKC δ , PKA, AKT1, ERK1, EGFR, CDK2, IKK β or CamK2 β . SK1-I enhances autophagy and has antitumor activity [2].

SK1-I ($0-10\ \mu M$; 24 hours) attenuates cancer cell growth and survival in a TP53-dependent manner in HCT116 cells and HCT116 cells bearing TP53 null cancer [2]. SK1-I ($0-20\ \mu M$; 12 hours) induces more CASP3 cleavage in HCT116 cells, compared to HCT116 cells lacking TP53, leading to a hallmark of apoptosis [2]. Cell Viability Assay [2] Cell Line: HCT116 cells and HCT116 cells bearing TP53 null cancer

Pre-treatment with SK1-I (BML-258; intraperitoneal (i.p.) injection; once; 24 hours prior to baseline mean arterial blood pressure (MAP) measurement; $75\ mg/kg$) before anandamide (i.v. injection; two doses; 1 and $10\ mg/kg$) significantly decreases the hypotensive response [3]. Animal Model: Male C57BL/6 mice ($24\pm 3.5\ g$) [3]

[1]. Melissa R Pitman, et al. Inhibitors of the sphingosine kinase pathway as potential

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

therapeutics. *Curr Cancer Drug Targets*. 2010 Jun;10(4):354-67. [2]. Santiago Lima, et al. TP53 is required for BECN1- and ATG5-dependent cell death induced by sphingosine kinase 1 inhibition. *Autophagy*. 2018;14(6):942-957. [3]. Fiona H Greig, et al. Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse. *Eur J Pharmacol*. 2019 Jan 5;842:1-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA